Immuno-Oncology Veteran Rachel Humphrey Joins CytomX
This article was originally published in Scrip
CytomX Therapeutics, Inc., a biopharmaceutical company developing therapeutics for the treatment of cancer, has appointed Dr. Rachel Humphrey chief medical officer. Humphrey formerly led immuno-oncology at Eli Lilly and AstraZeneca; oversaw clinical development of Yervoy (ipilmumab), the first FDA approved checkpoint inhibitor, at Bristol-Myers Squibb; and played a role in the development of Nexavar (sorafenib) at Bayer. She was also previously a member of CytomX's board of directors.
You may also be interested in...
Bristol-Myers Squibb expanded its collaboration with CytomX for $200m up front and up to $3.6bn in milestone fees. Also, Takeda spun out eight non-core molecules into a new joint venture and X-Chem executed two deals with Japanese partners, among other recent deals.
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.